KAI Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: South San Francisco CA United States (2003)
Status: Acquired by Amgen (2012)

Organization Overview

First Clinical Trial
2004
NCT00093197
First Marketed Drug
2017
etelcalcetide (parsabiv)
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

KAI Pharmaceuticals, Inc | KAI PHARMS INC

Active Ingredients

Marketed Drugs (1)

etelcalcetide (parsabiv) (2017)

Drugs in Phase 2 Trials (5)

delcasertib (2 trials)

etelcalcetide (parsabiv) (5 trials)

kai-1678 (3 trials)

ketorolac (acuvail) (1 trial)

lidocaine (xylocaine) (1 trial)

Drugs in Phase 1 Trials (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bone Diseases (Phase 2)

Cardiovascular Diseases (Phase 2)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 2)

Hyperparathyroidism (Phase 2)

Hyperparathyroidism, Secondary (Phase 2)

Infarction (Phase 2)

Kidney Diseases (Phase 2)

Myocardial Infarction (Phase 2)

Neoplasm Metastasis (Phase 2)

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Pain, Postoperative (Phase 2)

Pathologic Processes (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Spinal Cord Injuries (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 6